Journal of Neurology

, Volume 253, Issue 12, pp 1533–1541 | Cite as

News on the genetics, epidemiology, medical care and translational research of Schwannomas

  • C.O. Hanemann
  • D.G. Evans


Recent years have seen substantial news and updates in the genetics and diagnosis of schwannomas, even a new hereditary disease with schwannomas; Schwannomatosis has been defined. These developments have consequently led to better evaluation of the incidence of schwannomas. Although there has also been progress in the treatment of schwannomas especially in the field of radiation therapy, hereditary diseases with multiple tumours still represent a therapeutic dilemma. NF2 in particular still causes major morbidity and mortality owing to the neurological deficit of multiple tumour disease and deafness caused by vestibular nerve involvement. Thus there has been great enthusiasm about disease models in the hope that translational research will give rise to new therapies.


Schwannomas Neurofibromatosis 2 Schwannomatosis translational research review 


  1. 1.
    Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K (2001) Schwannoma of the extremities: the role of PET in preoperative planning. Eur J Nucl Med 28:1541–1551PubMedCrossRefGoogle Scholar
  2. 2.
    Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaeaeskelaeinen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas (see comments). Neurology 54:71–76PubMedGoogle Scholar
  3. 3.
    Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A (2000) Neurofibromatosis 2, radiosurgery and malignant nervous system tumours (letter). Br J Cancer 82:998PubMedCrossRefGoogle Scholar
  4. 4.
    Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715–723PubMedCrossRefGoogle Scholar
  5. 5.
    Baser ME, Friedman JM, Evans DG (2006) Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 66:730–732PubMedCrossRefGoogle Scholar
  6. 6.
    Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, Ramsden RT, Evans DG (2004) Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet 75:231–239PubMedCrossRefGoogle Scholar
  7. 7.
    Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98–101PubMedCrossRefGoogle Scholar
  8. 8.
    Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J (2005) Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 63:75–81PubMedCrossRefGoogle Scholar
  9. 9.
    Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313PubMedCrossRefGoogle Scholar
  10. 10.
    Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A (2005) Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2:574–579PubMedGoogle Scholar
  11. 11.
    Evans DG, Manson S, Huson SM, Pouder M, Harding AE, Strachan T (1997) Neurofibromatosis type 2: genetic and clinical features. Ear: J Neurol Neurosurg Psychiatry 62:361–366Google Scholar
  12. 12.
    Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12PubMedCrossRefGoogle Scholar
  13. 13.
    Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618PubMedGoogle Scholar
  14. 14.
    Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Medl Genet29:841–846Google Scholar
  15. 15.
    Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93–97PubMedCrossRefGoogle Scholar
  16. 16.
    Evans DG, Sainio M, Baser ME (2000) Neurofibromatosis type 2. J Med Genet 37:897–904PubMedCrossRefGoogle Scholar
  17. 17.
    Giovannini M, Robanus-Maandag E, van d V, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G (2000) Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Devel 14:1617–1630PubMedGoogle Scholar
  18. 18.
    Halliday AL, Sobel RA, Martuza RL (1991) Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg 74:248–253PubMedGoogle Scholar
  19. 19.
    Hanemann CO, Kaempchen KE, Kaufmann D, Krause BJ (2005) Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2. Arch Neurol 62:674–675PubMedCrossRefGoogle Scholar
  20. 20.
    Herwadker A, Vokurka EA, Evans DG, Ramsden RT, Jackson A (2005) Size and growth rate of sporadic vestibular schwannoma: predictive value of information available at presentation. Otol Neurotol 26:86–92PubMedCrossRefGoogle Scholar
  21. 21.
    Hirokawa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V, Maruta H (2005) Signal Therapy of NF1-Deficient Tumor Xenograft in Mice by the Anti-PAK1 Drug FK228. Cancer Biol Ther 4:379–381PubMedCrossRefGoogle Scholar
  22. 22.
    Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J, Maruta H (2004) A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 10:20–26PubMedCrossRefGoogle Scholar
  23. 23.
    Ho SY, Kveton JF (2002) Acoustic neuroma. Assessment and management. Otolaryngol Clin North Am 35:393–404, viiiPubMedCrossRefGoogle Scholar
  24. 24.
    Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO (2003) Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 12:1211–1221PubMedCrossRefGoogle Scholar
  25. 25.
    Kim P, Ebersold MJ, Onofrio BM, Quast LM (1989) Surgery of spinal nerve schwannoma. Risk of neurological deficit after resection of involved root. J Neurosurg 71:810–814PubMedGoogle Scholar
  26. 26.
    Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26:89–92PubMedCrossRefGoogle Scholar
  27. 27.
    Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T (2003) Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12:841–849PubMedCrossRefGoogle Scholar
  28. 28.
    Klekamp J, Samii M (1998) Surgery of spinal nerve sheath tumors with special reference to neurofibromatosis. Neurosurgery 42:279–289PubMedCrossRefGoogle Scholar
  29. 29.
    Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40:109–114PubMedCrossRefGoogle Scholar
  30. 30.
    Lim JY, Kim H, Kim YH, Kim SW, Huh PW, Lee KH, Jeun SS, Rha HK, Kang JK (2003) Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 302:238–245PubMedCrossRefGoogle Scholar
  31. 31.
    MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES (2005) Diagnostic criteria for schwannomatosis. Neurology 64:1838–1845PubMedCrossRefGoogle Scholar
  32. 32.
    Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH (2004) Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 25:150–154PubMedCrossRefGoogle Scholar
  33. 33.
    Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg 96:223–228PubMedCrossRefGoogle Scholar
  34. 34.
    Mautner VF, Tatagiba M, Lindenau M, Funsterer C, Pulst SM, Baser ME, Kluwe L, Zanella FE (1995) Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 165:951–955PubMedGoogle Scholar
  35. 35.
    McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T (1998) Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Devel 12:1121–1133PubMedGoogle Scholar
  36. 36.
    Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO (2005) Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2. Hum Gene TherGoogle Scholar
  37. 37.
    Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO (2002) Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 4:501–509PubMedCrossRefGoogle Scholar
  38. 38.
    Mohyuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DG (2003) Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40:459–463CrossRefGoogle Scholar
  39. 39.
    Murray AJ, Hughes TA, Neal JW, Howard E, Evans DG, Harper PS (2006) A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J Neurol Neurosurg Psychiatry 77:269–271PubMedCrossRefGoogle Scholar
  40. 40.
    Nyberg G, Bergstrom M, Enblad P, Lilja A, Muhr C, Langstrom B (1997) PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol 117:482–489PubMedGoogle Scholar
  41. 41.
    Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF (1996) Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59:529–539PubMedGoogle Scholar
  42. 42.
    Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM (2001) Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 218:434–442PubMedGoogle Scholar
  43. 43.
    Rosenbaum C, Kamleiter M, Grafe P, Kluwe L, Mautner V, Muller HW, Hanemann CO (2000) Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. Neurobiol Dis 7:483–491PubMedCrossRefGoogle Scholar
  44. 44.
    Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO (1998) Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 5:55–64PubMedCrossRefGoogle Scholar
  45. 45.
    Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA (2003) Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74:1288–1293PubMedCrossRefGoogle Scholar
  46. 46.
    Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331–342PubMedGoogle Scholar
  47. 47.
    Sakamoto H, Nakai Y, Matsuda M, Ohashi Y, Tsuyuguchi N, Kawabe J, Okamura T, Ochi H (2000) Positron emission tomographic imaging of acoustic neuromas. Acta Otolaryngol Suppl 542:18–21PubMedCrossRefGoogle Scholar
  48. 48.
    Samii M, Matthies C (1997) Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Neurosurgery 40:248–260PubMedCrossRefGoogle Scholar
  49. 49.
    Samii M, Matthies C (1997) Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve–preservation and restitution of function. Neurosurgery 40:684–694PubMedCrossRefGoogle Scholar
  50. 50.
    Schneider J, Warzok R, Schreiber D, Guthert H (1983) [Tumors of the central nervous system in biopsy and autopsy material. 7th communication: neurinomas and neurofibromatoses with CNS involvement]. Zentralbl Allg Pathol 127:305–314PubMedGoogle Scholar
  51. 51.
    Schulze KM, Hanemann CO, Muller HW, Hanenberg H (2002) Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11:69–76PubMedCrossRefGoogle Scholar
  52. 52.
    Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM (2002) Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 11:3179–3189PubMedCrossRefGoogle Scholar
  53. 53.
    Scoles DR, Qin Y, Nguyen V, Gutmann DH, Pulst SM (2005) HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun 335:385–392PubMedCrossRefGoogle Scholar
  54. 54.
    Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O’Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI (2001) The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1:63–72PubMedCrossRefGoogle Scholar
  55. 55.
    Slattery WH III, Fisher LM, Iqbal Z, Oppenhiemer M (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:811–817PubMedCrossRefGoogle Scholar
  56. 56.
    Sobel RA (1993) Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 52:106–113PubMedGoogle Scholar
  57. 57.
    Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO (2002) Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 125:996–1004PubMedCrossRefGoogle Scholar
  58. 58.
    Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRefGoogle Scholar
  59. 59.
    Tos M, Charabi S, Thomsen J (1999) Incidence of vestibular schwannomas. Laryngoscope 109:736–740PubMedCrossRefGoogle Scholar
  60. 60.
    Utermark T, Kaempchen K, Hanemann CO (2003) Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol 13:352–363PubMedCrossRefGoogle Scholar
  61. 61.
    Utermark T, Schubert SJ, Hanemann CO (2005) Rearrangements of the intermediate filament GFAP in primary human schwannoma cells. Neurobiol Dis 19:1–9PubMedCrossRefGoogle Scholar
  62. 62.
    Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG (2003) Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. J Med Genet 40:802–806PubMedCrossRefGoogle Scholar
  63. 63.
    Woods R, Friedman JM, Evans DG, Baser ME, Joe H (2003) Exploring the “two-hit hypothesis” in NF2: tests of two-hit and three-hit models of vestibular schwannoma development. Genet Epidemiol 24:265–272PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  1. 1.Clinical NeurobiologyInst. Biomedical and Clinical Science, Peninsula Medical SchoolPlymouthUK
  2. 2.Academic Unit of Medical GeneticsSt Mary’s HospitalManchesterUK

Personalised recommendations